R6152

Ranolazine dihydrochloride

≥98% (HPLC), powder, Na⁺-current blocker

• Sinónimos: (±) -4-[2-Hydroxy-3-(o-methoxyphenoxy)propyl]-1-piperazineaceto-2′,6′-xylidide dihydrochloride, N-(2,6-Dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazineacetamide dihydrochloride
• Fórmula empírica (notación de Hill): C₂₄H₃₃N₃O₄ · 2HCl
• Número CAS: 95635-56-6
• Peso molecular: 500.46
• UNSPSC Code: 12352200
• PubChem Substance ID: 24278795
• NACRES: NA.77
• MDL number: MFCD03788770

Propiedades

• Nombre del producto: Ranolazine dihydrochloride, ≥98% (HPLC), powder
• SMILES string: Cl.Cl.COc1ccccc1OCC(O)CN2CCN(CC2)CC(=O)Nc3c(C)cccc3C
• InChI key: RJNSNFZXAZXOFX-UHFFFAOYSA-N
• InChI: 1S/C24H33N3O4.2ClH/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3;;/h4-10,20,28H,11-17H2,1-3H3,(H,25,29);2*1H
• assay: ≥98% (HPLC)
• form: powder
• storage condition: desiccated
• color: white to beige
• mp: 222-229.5 °C (lit.)
• solubility: H₂O: soluble ≥10 mg/mL
• originator: Gilead
• Quality Level: 100
• Gene Information: human ... SCN4A(6329), SCN5A(6331)

Descripción

Biochem/physiol Actions

pFOX (partial fatty acid oxidation) inhibitor, a new class of anti-anginal drugs, which inhibit fatty acid beta-oxidation and activates pyruvate dehydrogenase, thereby diverting the heart′s energy source from lipids to glucose, which requires less oxygen and helps maintain myocardiac function at times of ischemia

Ranolazine is a derivative of anti-ischemic piperazine[1] and acts as sodium (Na⁺)-current inhibitor.[2] It has the potential to treat diastolic heart failure and helps in ameliorating myocardial diastolic function.[1]

Application

Ranolazine dihydrochloride has been used:

• as a low Torsades-de-pointes (TdP) risk drug to study its effects on QTc prolongation, electrocardiographic (PR and QRS) intervals in dog cardiovascular model[3]
• as a partial fatty acid oxidation (FAO) inhibitor to study its effects on glioblastoma cells[4]
• as a late sodium(Na⁺)-current (INaL) inhibitor to study its effects on atrial tachycardia in rabbit heart[2]

Features and Benefits

This compound was developed by Gilead. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable
• ppe: Eyeshields, Gloves, type N95 (US)